Abstract: A connector for use in a respiratory system. The connector can connect a first respiratory system component such as a filter to a second respiratory system component. The connector has a body defining a bore for receipt of a complementary connector component. The bore has a terminal end that provides an entry into the bore for the complementary connector component. The connector comprises at least one internal retaining feature, at least one internal alignment feature, and/or at least one external alignment feature.

Abstract: A conductive terminal includes a first pair of clamping arms forming a first clamping portion for connecting with a wire, and a second pair of clamping arms connected to the first pair of clamping arms by a connecting part. The first clamping portion has a first clamping sub-portion and a second clamping sub-portion distributed along a length direction. The second pair of clamping arms forms a second clamping portion. The second clamping portion has a third clamping sub-portion and a fourth clamping sub-portion distributed along the length direction. The first clamping sub-portion corresponds to the third clamping sub-portion in the length direction. A width of the first clamping sub-portion is greater than a width of the third clamping sub-portion. The second clamping sub-portion corresponds to the fourth clamping sub-portion in the length direction. A width of the second clamping sub-portion is less than a width of the fourth clamping sub-portion.

Abstract: An insulation displacement contact (IDC) cluster includes a plurality of IDC cluster modular units each having a plurality of receptacles adjacent to one another in a row. Each of the receptacles receives an IDC terminal. A first IDC cluster modular unit of the IDC cluster modular units is coupled to a second IDC cluster modular unit of the IDC cluster modular units to form a modular structure by stacking and fastening together, arranging the receptacles of the IDC cluster modular units in parallel rows.

Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I: and to pharmaceutical compositions having antitumor action.

Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general and to pharmaceutical compositions having antitumor action.

Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I: 1

Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I and to pharmaceutical compositions having antitumor action.

Abstract: The invention relates to novel indole and heteroindole derivatives of the formula I 1

Abstract: The object of the invention is then to widen the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available pharmaceutical wealth. The possibility of a lower, longer-lasting and better-tolerable medication for the class of substances having antitumor action described in German Patent Application 19814 838.0 should thus be opened up. In particular, the disadvantageous development of resistance, as is known of many antitumor agents, should be circumvented.

Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Abstract: The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Abstract: The invention relates to novel indole and heteroindole derivatives of the formula I 1

Abstract: This invention relates to novel xanthone compounds, their preparation and use as medicament. More particularly this invention is directed to the isolation of the novel xanthone natural product sootepenseone from Dasymaschalon sootepense Craib, Annonaceae, its identification and derivatization, and the use of sootepenseone and its derivatives as anticancer agents.

Abstract: An adaptor for connecting a chip card to a PCMCIA-standard computer slot has a housing with a top cover, a separate bottom cover, and at least one intermediate insulative element or frame connecting the top cover to the bottom cover at a spacing to one another. The top cover and bottom cover have substantially congruent outer contours. The housing has a receiving channel. A printed circuit board is mounted in the housing and extends parallel to the receiving channel. The circuit board has contact elements for electrically contacting a chip card received in the receiving channel. The housing has a front face and a back face wherein the front face has an insertion slot communicating with the receiving channel. The back face has a contact plug electrically connected to the printed circuit board and adapted to electrically contact the PCMCIA-standard computer slot. Cams at the channel entrance are used for card retention.

Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Abstract: New LH-RH antagonists are disclosed, in particular peptidomimetics and peptides modified in a side chain, their salts with pharmaceutically acceptable acids and a process for preparing these LH-RH antagonists and their salts. The disclosed peptides represent analogues of the luteinising hormone releasing hormone (LH-RH). The disclosed compounds have a high antagonistic power and are free of undesirable side effects, in particular edematogenic effects.

Abstract: The invention describes a novel method for determining the mass of vital tumor cells of xenotransplants in animal models. Cells altered by genetic engineering which form a tumor after transplantation synthesize an excreted reporter gene. This is shown by way of example for a secreted form of human placenta-specific, alkaline phosphate (SEAP). The latter can be demonstrated in the serum of test animals or in culture supernatants. The activity of SEAP in the serum correlates with the number of vital tumor cells in the animal and can be measured prior to the formation of a palpable tumor. The invention shows the use of cell lines altered by genetic engineering in such a manner in subcutaneous and orthotopic tumor models. Dicistronic, eukaryotic expression vectors are used for the stable transfection of the mammalian cell lines or tumor cells used. These vectors contain, under the control of a constitutive or inducible promotor element, the gene coding for SEAP, coupled with a second gene.